Efficacy of bicalutamide in the treatment of prostate cancer
10.3760/cma.j.issn.1008-6706.2020.11.003
- VernacularTitle:比卡鲁胺治疗前列腺癌的疗效研究
- Author:
Zhaoyang XU
1
;
Quanfa ZHONG
Author Information
1. 浙江省，建德市第一人民医院病理科 311600
- From:
Chinese Journal of Primary Medicine and Pharmacy
2020;27(11):1290-1293
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the therapeutic effect of bicalutamide on prostate cancer.Methods:Ninety-five patients with prostate cancer in the First People's Hospital of Jiande were selected from January 2014 to January 2019.All 95 patients received blood samples before treatment were selected as case group, and 85 healthy subjects were selected as control group.The clinical symptoms of the patients before treatment and after treatment with bicalutamide for 3, 6, 9, 12 months were recorded.The blood samples were taken as the treatment group at 12 months after treatment.The effect of bicalutamide on the expression of miRNA-125b and miRNA-21 in serum of patients with prostate cancer was detected by RT-PCR.Results:After treatment, the prostate volume and serum prostate specific antigen (PSA) expression were significantly reduced(3 months after treatment compared with before treatment, prostate volume: t=6.22, P=0.00; PSA: t=5.14, P=0.00; 6 months after treatment compared with before treatment, prostate volume: t=8.32, P=0.00; PSA: t=4.11, P=0.00; 12 months after treatment compared with before treatment, prostate volume: t=10.14, P=0.00; PSA: t=9.25, P=0.00; 6 months after treatment compared with 3 months after treatment, prostate volume: t=3.82, P=0.00; PSA: t=6.23, P=0.00; effective rate: χ 2=6.38, P=0.00.One year after treatment compared with 3 months after treatment, prostate volume: t=4.16, P=0.00; PSA: t=5.77, P=0.00; effective rate: χ 2=5.74, P=0.00.One year after treatment compared with 6 months after treatment, the prostate volume: t=8.11, P=0.00; PSA: t=4.92, P=0.00; effective rate: χ 2=4.44, P=0.00). And with the extension of treatment time, the treatment effect was significantly enhanced.RT-PCR results showed that compared with the control group, the expression levels of miRNA-125b and miRNA-21 in the case group were significantly increased( t=6.22, 6.88, P=0.01, 0.00). After treatment with bicalutamide, the levels of miRNA-125b and miRNA-21 in serum of prostate cancer patients were significantly reduced. Conclusion:Bicalutamide can reduce the pain and increase the efficacy of prostate cancer patients; bicalutamide can reduce the expression of miRNA-125b and miRNA-21 in serum of patients with prostate cancer.
